Welcome to our dedicated page for Firefly Neuroscience news (Ticker: AIFF), a resource for investors and traders seeking the latest updates and insights on Firefly Neuroscience stock.
Firefly Neuroscience, Inc. develops AI-enabled precision neuroscience tools built around EEG/ERP brain data, including its FDA 510(k)-cleared brain analytics technology, the BNA platform, the Evoke System and the CLEAR Platform. News about AIFF centers on commercialization of cognitive electrophysiology analytics, growth in brain scan volumes, expansion of its standardized EEG/ERP data repository, and the use of NVIDIA GPU acceleration for signal processing and biomarker discovery.
Recurring company updates also cover research applications in neurological and mental health conditions such as ADHD, depression, dementia, anxiety disorders, concussions and cognitive disorders; partnerships with clinics, researchers and institutional customers; integration of Evoke Neuroscience; and periodic financial results tied to equipment sales, rentals, per-use fees and services for projects or clinical studies.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on brain health solutions, has appointed Dr. Stella Vnook to its Board of Directors, effective August 19, 2024. Dr. Vnook, with over 25 years of experience in pharmaceuticals and biotechnology, will serve as Chairperson of the Nominating Committee. She brings expertise as a pharmaceutical executive, entrepreneur, and founder of multiple biotech companies.
Currently, Dr. Vnook is the CEO of Likarda Biotech and Founder and Chair of OralBiolife Biosciences. She also advises several startups and supports innovation at various universities. Her background includes roles at Merck, Jazz Pharmaceuticals, and Catalant. Dr. Vnook holds multiple science degrees, an MBA in Global Marketing, and a Doctorate in Public Health focused on Health Economics.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on improving brain health outcomes, announced that CEO Jon Olsen will present at the H.C. Wainwright's 26th Annual Global Investment Conference on September 11, 2024, at 1:30 p.m. ET. The event will be held at the Lotte New York Palace Hotel.
Olsen will discuss recent corporate milestones, including the merger with WaveDancer and Firefly's FDA-510(k) cleared Brain Network Analytics (BNA™) platform. This innovative technology aims to support clinicians in diagnosing and optimizing patient care for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Investors can schedule one-on-one meetings with Olsen and Chief Medical Officer Dr. Samer Kaba. A webcast of the presentation will be available, with a 90-day replay accessible on the company's website.
Firefly Neuroscience (NASDAQ: AIFF), an AI-driven brain health company, has announced a shareholder update call scheduled for September 4, 2024, at 5:00 PM EST. The company, which focuses on developing innovative neuroscientific solutions for mental illnesses and neurological disorders, will provide investors with the latest information about its operations and progress.
Shareholders and interested parties can register for the webinar through the provided Zoom link. This update call presents an opportunity for investors to gain insights into Firefly's advancements in AI technology applied to brain health and its potential impact on patient outcomes.
Firefly Neuroscience (NASDAQ: AIFF) has formed a strategic partnership with Neurology Consultants of Dallas (NCD) to enhance early detection and management of cognitive disorders. NCD will integrate Firefly's Brain Network Analytics (BNA) technology into its patient protocols and conduct clinical studies to identify biomarkers for predicting dementia onset. This collaboration aims to optimize patient care pathways and improve outcomes for those suffering from cognitive decline.
The partnership highlights the clinical value of BNA technology in providing diagnostic insights and trending analysis for conditions such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis. By establishing cognitive baselines, healthcare providers can more accurately track changes and promote early detection. This integration is expected to enhance neurology testing for millions of U.S. patients by encouraging widespread adoption of advanced diagnostic tools.
Firefly Neuroscience (NASDAQ: AIFF) has completed its merger with WaveDancer and is now listed on Nasdaq. The company focuses on using AI to improve brain health outcomes through two key strategies:
1. Commercializing FDA-cleared Brain Network Analytics (BNA™) technology for neurologists in the US.
2. Partnering with CNS drug companies to advance new treatments for brain disorders.
BNA™ has shown promising results in patient care, reducing medication changes and improving recovery times. Firefly plans to make BNA™ commercially available to neurologists in 2025. The company has already partnered with Novartis, Takeda, and STALICLA SA, featuring in three publications in 2024. Firefly's proprietary database of over 17,000 patients across 12 disorders gives it a competitive advantage in developing clinical biomarkers.